WealthPlan Investment Management LLC Acquires 10,256 Shares of Gilead Sciences, Inc. $GILD

WealthPlan Investment Management LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 316.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 13,494 shares of the biopharmaceutical company’s stock after buying an additional 10,256 shares during the quarter. WealthPlan Investment Management LLC’s holdings in Gilead Sciences were worth $1,656,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Noesis Capital Mangement Corp lifted its stake in shares of Gilead Sciences by 0.7% during the 4th quarter. Noesis Capital Mangement Corp now owns 115,263 shares of the biopharmaceutical company’s stock worth $14,147,000 after acquiring an additional 745 shares during the last quarter. Lawood & Co. bought a new position in Gilead Sciences in the fourth quarter worth approximately $633,000. AlphaCore Capital LLC grew its stake in Gilead Sciences by 42.9% in the fourth quarter. AlphaCore Capital LLC now owns 17,327 shares of the biopharmaceutical company’s stock worth $2,127,000 after purchasing an additional 5,199 shares in the last quarter. DNB Asset Management AS grew its stake in Gilead Sciences by 3.8% in the fourth quarter. DNB Asset Management AS now owns 254,443 shares of the biopharmaceutical company’s stock worth $31,230,000 after purchasing an additional 9,326 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd bought a new position in Gilead Sciences in the fourth quarter worth approximately $68,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

GILD opened at $129.58 on Monday. The firm has a market cap of $160.88 billion, a price-to-earnings ratio of 17.65 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12 month low of $100.23 and a 12 month high of $157.29. The stock has a fifty day moving average price of $137.76 and a 200-day moving average price of $133.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. BMO Capital Markets increased their price objective on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, January 26th. Argus increased their price objective on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Deutsche Bank Aktiengesellschaft increased their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada dropped their price objective on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a research note on Friday, May 8th. Finally, Mizuho increased their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $157.04.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the sale, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock worth $9,238,250 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.